Free Trial

Harrow Q3 2023 Earnings Report

Harrow logo
$28.95 -1.18 (-3.92%)
As of 02/21/2025 04:00 PM Eastern

Harrow EPS Results

Actual EPS
-$0.09
Consensus EPS
$0.03
Beat/Miss
Missed by -$0.12
One Year Ago EPS
-$0.06

Harrow Revenue Results

Actual Revenue
$34.27 million
Expected Revenue
$37.58 million
Beat/Miss
Missed by -$3.31 million
YoY Revenue Growth
+50.10%

Harrow Announcement Details

Quarter
Q3 2023
Time
After Market Closes

Conference Call Resources

Harrow Earnings Headlines

The Real Hillbilly Elegy
The mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky, Tennessee and beyond… It's one of our country’s most scenic areas. But hidden beneath the beauty is an ugly reality: our most beautiful land is also the poorest. It’s a tragedy because for over 200 years, generation after generation has worked “coal country” with nothing but a pick and shovel, hauling billions of dollars from the ground.
Research Analysts Issue Forecasts for Harrow Q4 Earnings
Harrow initiated with a Buy at H.C. Wainwright
See More Harrow Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Harrow? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Harrow and other key companies, straight to your email.

About Harrow

Harrow (NASDAQ:HROW) operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

View Harrow Profile

More Earnings Resources from MarketBeat